What we do
Equity products
Technology Transfer
European Angels Fund (EAF) - Co-investments with Business Angels
Venture capital
The Social Impact Accelerator (SIA)
Lower mid-market
Mezzanine Facility for Growth
Pan-European Venture Capital Fund(s)-of-Funds programme
EFSI Equity instrument
Single EU Equity Financial Instrument
COSME - Equity Facility for Growth
InnovFin Equity
Private equity secondary market transactions
EIF-NPI Equity Platform
Debt products
AGRI Guarantee Facility
AGRI Italy Platform Uncapped Guarantee Instrument
Credit enhancement
Cultural and Creative Sectors Guarantee Facility (CCS GF)
ENSI - Securitisation Initiative
Erasmus+ Master Loan Guarantee Facility
EREM debt products
Single EU Debt Financial Instrument
COSME - Loan Guarantee Facility
InnovFin SME Guarantee Facility
Documentary Finance Facility – Bulgaria
The SME Initiative
The SME Initiative Bulgaria
The SME Initiative Finland
The SME Initiative Italy
The SME Initiative Malta
The SME Initiative Romania
The SME Initiative Spain
Asset Management Umbrella Fund (AMUF)
Inclusive finance
EaSI Financial Instruments
EaSI Capacity Building Investments Window
EaSI Guarantee Instrument
European Progress Microfinance Facility
Entrepreneurs supported through Progress Microfinance
European Fund for Strategic Investments (EFSI)
How does EIF contribute to EFSI
How to apply for EFSI financing
Regional Development - Country and sector-specific initiatives
Croatian Growth Investment Programme (CROGIP)
AGRI Italy Platform Uncapped Guarantee Instrument
ALTER’NA – ESIF EARFD Nouvelle-Aquitaine
Baltic Innovation Fund (BIF)
Central Europe Fund of Funds (CEFoF)
Croatian Venture Capital Initiative (CVCi FoF)
Competitiveness Fund-of-Funds for SMEs in Romania
Deep and Comprehensive Free Trade Area Initiative East Guarantee Facility (DCFTA)
Dutch Growth Co-Investment Programme
Dutch Venture Initiative (DVI-II)
EAFRD FoF Romania
European Recovery Programme (ERP)
ERP-EIF Co-Investment Growth Facility
INAF – French National Agricultural Initiative
Regional Fund-of-Funds Romania
ESIF Fund-of-Funds Czech Republic
ESIF Fund-of-Funds Greece
The Silesia EIF Fund of Funds
La Financière Région Réunion
The EIB Group Risk Enhancement Mandate (EREM)
EstFund
FOSTER TPE-PME Occitanie
Greater Anatolia Guarantee Facility (GAGF)
G43 - Anatolian Venture Capital Fund Project
InvestBG Equity Instrument
JEREMIE
JEREMIE Romania Reflows – Equity Instrument
LfA-EIF Facility
Luxembourg Future Fund (LFF)
Mezzanine 'Fund of Fund' for Germany (MDD)
Polish Growth Fund of Funds (PGFF)
Portugal Venture Capital Initiative (PVCi)
Scottish-European Growth Co-Investment Programme
Slovene Equity Growth Investment Programme (SEGIP)
Swedish Venture Initiative (SVI)
Turkish Growth and Innovation Fund (TGIF)
Western Balkans Enterprise Development & Innovation Facility (WB EDIF)

How EFSI benefits SMEs in Europe - Ysios Biofund II Innvierte case study: Aelix (Spain), Life Sciences

image

AELIX Therapeutics is a drug development company specialized in the development of a therapeutic vaccine (not to be confused with preventive vaccines) that will be used in cure and eradication strategies against HIV infection. “The vaccine will re-educate the immune system of patients so that they can control their HIV infection without further antiretroviral therapy” explains Jordi Naval, co-founder and Director at AELIX.

If this replaces traditional antiretroviral treatment, it could have the benefit of doing away with adverse side-effects, improving quality of life and also impacting healthcare budgets.

Based in Barcelona, AELIX is a truly European project, with partners all over Europe: Research partners in the Netherlands, regulatory consultants in Belgium and France, and manufacturing partners in Germany, the UK and Italy.

The company is a spin-off from IrsiCaixa, a public-private consortium conducting cutting-edge research in the field of AIDS and related diseases.  Set up in 2015, AELIX benefitted from an investment from Ysios Capital, which allowed the company to take key steps in the development of its product. With this financing, the company was able to finalise the regulatory and production processes, and proceed with clinical trials. “We are now in clinics, working with HIV patients and we expect results by mid-2020. If all goes well, our product could be administered to millions of HIV patients across the whole world” Jordi adds. It is estimated that more than 37 million people in the world are HIV-positive.

“We believe that AELIX’s innovative approach has the potential to radically transform the treatment of HIV infection, still one of the largest health problems in the world,” says Karen Wagner from Ysios Capital. “We were impressed by the science and the preclinical data. This may indeed help to improve the health of millions of people globally.”

One of the benefits of equity financing is the expertise that comes with the investment and this is something that Jordi agrees with: “Ysios have added invaluable expertise to the company. They’ve been instrumental, beyond the financing, to the governance of the company, bringing a lot in terms of the ‘right way to do things’ both operationally and at the corporate level.

Company: Aelix Therapeutics (Spain)

Type of business: Life Sciences

EIF financing: InnovFin Equity, EFSI

Financial intermediary: Ysios Biofund II Innvierte

For further information about EIF intermediaries in Spain, please refer to: http://www.eif.org/what_we_do/where/es


 
 

Copyright ©

 European Investment Fund 2019 – The European Investment Fund is not responsible for the content of external internet sites.